Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)
Frontiers in Oncology · 28.07.2026 · 16
DOI: 10.3389/fonc.2026.1798502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.07.2026. Verfasst von Trisha M Wise-Draper und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vusolimogene oderparepvec (RP1) is an intratumorally administered, genetically modified herpes simplex virus type-1 derived oncolytic immunotherapy designed to selectively replicate in tumors and stimulate systemic antitumor immunity. We evaluated the biodistribution, shedding, and potential for transmission of RP1 in patients with skin cancers treated in the IGNYTE clinical trial and assessed close-contact exposure across all RP1 clinical studies.
Methods
Patients received intratumoral RP1 in combination with nivolumab, with serial collection of blood, urine, injection-site, dressing, and oral mucosal samples during treatment and follow-up. RP1 DNA was quantified by polymerase chain reaction, and swab samples positive for RP1 DNA were tested for replication-competent RP1. Reports of herpetic infection in patients and close contacts were also systematically collected.
Results
Among 282 treated patients, RP1 DNA was detected most frequently at injection sites, with substantially lower incidence and levels in other sample types. Detection declined rapidly after treatment completion, with no RP1 DNA detected in blood or urine during follow-up. Replication-competent RP1 was detected rarely and only at low titers, only at injection sites. No systemic herpes simplex virus infections occurred in patients, and no herpetic infections were reported among caregivers or close contacts.
Interpretation
RP1 is largely confined to injection sites, shedding of live RP1 is rare and transient. No evidence of transmission of RP1 was observed. These findings support the favorable biosafety profile of RP1 with only a negligible risk of environmental release or secondary transmission during clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, OH, United States.
- Gustave Roussy and Paris-Saclay University, Villejuif, France.
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
- Churchill Hospital, University of Oxford, Oxford, United Kingdom.
- The Clatterbridge Cancer Centre, Wirral, United Kingdom.
- University of Liverpool, Liverpool, United Kingdom.
Zitieren
APA
Wise-Draper, T. M., Robert, C., Wong, M. K., Middleton, M. R., Sacco, J. J., In, G. K., Muñoz Couselo, E., Schadendorf, D., Beasley, G. M., Niu, J., Chmielowski, B., Milhem, M. M., Bowles, T. L., Tsai, K. K., Samson, A., Harrington, K. J., Lebbé, C., Gaudy-Marqueste, C., Zhu, J., …, & Bommareddy, P. K. (2026). Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1798502
Vancouver
Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, et al. Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1798502
BibTeX
@article{WiseDraper2026,
author = {Wise-Draper, Trisha M and Robert, Caroline and Wong, Michael K and Middleton, Mark R and Sacco, Joseph J and In, Gino K and Muñoz Couselo, Eva and Schadendorf, Dirk and Beasley, Georgia M and Niu, Jiaxin and Chmielowski, Bartosz and Milhem, Mohammed M and Bowles, Tawnya Lynn and Tsai, Katy K and Samson, Adel and Harrington, Kevin J and Lebbé, Céleste and Gaudy-Marqueste, Caroline and Zhu, Junhong and Paratala, Bhavna and Hou, Jeannie W and Xynos, Kostas and Clack, Aaron and Coffin, Robert S and Bommareddy, Praveen K},
title = {Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1798502}
}
EUVIMED